Physician profile
Nathaniel Mattison
NPI 1073180758
$1,303.34
in general payments reported to CMS, 2019-2025
15 companies · $746 in 2025
The $746 reported for 2025 was more than what 94% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $30.29 · 2024: $528 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.35 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $353.31 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $211.58 | 2024-2025 | Tezspire, Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $134.45 | 2024-2025 | Zerbaxa, Winrevair |
| Glaxosmithkline, LLC. | $112.19 | 2024-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.50 | 2024-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $78.54 | 2024-2025 | Glassia |
| Insmed, INC. | $73.96 | 2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $56.19 | 2024-2025 | Dupixent |
| Abbvie INC. | $45.99 | 2023-2024 | |
| Genzyme Corporation | $39.29 | 2025 | |
| Alexion Pharmaceuticals, INC. | $34.39 | 2024-2025 | Ultomiris |
| Abiomed | $17.93 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $17.14 | 2024 | Xarelto |
| La Jolla Pharmaceutical Company | $15.28 | 2024 | Giapreza |
| Verona Pharma, INC. | $14.60 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Mattison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.